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A system is described for chronic intracranial drug administration in the rat using a modified in vivo microdialysis probe 
coupled to an Alzet model 2002 osmotic minipump. The results presented demonstrate that this system can be used for the chronic 
administration of quinolinic acid with minimal non-specific damage. Each pump delivered approximately 225 ~1 of solution over a 
period of 19-20 days when tested in vitro. The dialysis units were uniform in function, delivering > 93% of the [3H]quinolinic acid 
initially loaded into the minipump. For in vivo analysis of this apparatus the dose of quinolinic acid tested produced extensive 
destruction of the striatum. The present system allows reliable drug diffusion over a relatively large area without pressure injection 
variability. In conclusion, we have developed a simple and inexpensive technique for administration of drugs into brain parenchyma 
with substantial advantages over previously used techniques. 
Introduction 
Chronic drug administration in vivo has been 
demonstrated repeatedly using Alzet osmotic 
minipumps implanted either subcutaneously or 
intraperitoneally (Nielsen, 1981; Mendel et al., 
1988; Rivier and Vale, 1989; Sasamura et al., 
1990). Osmosis of extracellular fluid into the 
pump displaces the fluid within an internal reser- 
voir and causes slow release of the solution con- 
tained within the pump. Drug administration by 
this method can be local, at the site of the pump, 
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or distal if a section of flexible tubing is attached. 
For example, several researchers have reported 
successful intracranial infusion of drugs by at- 
tachment of a subcutaneous pump to a chroni- 
cally implanted intracranial cannula (Mangano 
and Schwarcz, 1983; McBean and Roberts, 1984; 
Hargraves and Freed, 1987; Rieke et al., 1989). 
This method of administration is generally un- 
complicated for intraventricular infusion. There 
are problems, however, with using this technique 
for chronic infusion into brain parenchyma. Can- 
nulae provide only a point source of drug, and 
this delivery method may produce non-specific 
damage due to the volume of fluid introduced. 
Furthermore, while some drugs may diffuse freely 
through tissue, unique properties of other sub- 
stances limit diffusion to a small region surround- 
ing the cannula tip, thus limiting the area af- 
fected by drug infusion (Evans et al., 1975). Fi- 
nally, incomplete expulsion of fluid by the pump, 
possibly caused by cannula obstruction, has also 
been reported (Hargraves and Freed, 1987). 
To reduce problems associated with chronic 
infusion using intracranial cannulae, a novel ap- 
paratus was developed that uses a modified in 
vivo microdialysis probe coupled with an Alzet 
minipump. The present report describes the suc- 
cessful in vitro and in vivo use of this apparatus 
to deliver the excitotoxin, quinolinic acid (QUIN), 
to the striatum. 
Methods 
Probe construction 
The design of the chronic microdialysis appa- 
ratus is shown schematically in Figs. 1 and 2 with 
dimensions for intrastriatal administration. The 
microdialysis section of the apparatus is adapted 
from an in vivo microdialysis probe (Robinson 
and Camp, 1991). The cost of materials is less 
than $7.50 plus the cost of the osmotic minipump. 
The assembly is constructed over 3 days, allowing 
epoxy compounds to dry overnight. 
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Fig. 1. A schematic illustration of the components  used to construct a chronic microdialysis apparatus  designed for intrastriatal 
delivery in the adult rat. 
Step 1. A 20-mm length of 26-ga thin wall 
stainless steel tubing is cut; the ends and lumen 
are cleaned. The cannula is then acid etched to 
facilitate epoxy adhesion using the following pro- 
cedure: (1) degrease in xylene for 5 rain, (2) acid 
pickle in 4% HzSO 4, 4% HCI in water for 20 
min, (3) acid etch in 12% HNO3, 2% hydrofluoric 
acid in water  for 15 rain, and (4) rinse in water 
then in methanol,  and dry. 
A 10-12-mm length of dialysis fiber is cut with 
iris scissors, taking care that the end has not been 
crimped. Using a fine pair of watchmaker  forceps 
to grasp one end, the dialysis fiber is inserted into 
one end of the stainless steel cannula with 7-8-  
mm protruding. Using a no. 00 insect pin, a small 
amount of 2-ton epoxy is applied around the 
circumference of the dialysis fiber adjacent to the 
cannula. The dialysis fiber is tapped further into 
the cannula so that the epoxy adheres to the 
inside of the cannula. The protruding dialysis 
fiber is cut to 4.25 mm from the epoxy 'collar. '  A 
small drop of epoxy is applied to the end of the 
dialysis fiber to close the end. Capillary action 
should draw the epoxy approximately 0.25 mm 
into the fiber. Allow to dry overnight. 
Step 2. A 13-cm length of fused silica capil- 
lary tubing is cut using a diamond edge cutter. 
Using a 30-ga needle, the fused silica tubing is 
drawn through the side wall and out one end of 
an 8-cm length of PE20 tubing (Fig. 1.) The fused 
silica is inserted into the open end of the stainless 
s teel /dialysis  fiber piece made in step 1 and 
pushed through the stainless steel cannula into 
the dialysis fiber (0.25 mm from the end). The 
PE20 tubing is pressure fit over the end of the 
cannula and the exposed end of the fused silica is 
Fig. 2. A chronic infusion apparatus ready for implantation. The pipette tip sleeve shown was securely fitted to the probe prior to 
implantation and cemented in place upon completion of the procedure. 
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threaded through an 8-cm length of Micro-line 
(TM) 1810 tubing. 
The narrow end of a 200~~1 pipette tip is cut 
so that a IO-mm length of Micro-line 1850 tubing 
will fit firmly in place with 4 mm extending from 
the pipette tip (see Fig. 1). The 26-ga stainless 
steel tubing with attached dialysis fiber is then 
carefully guided down the pipette tip and through 
the Micro-line tubing until the PE20 tubing con- 
tacts the Micro-line tubing. The pipette tip is 
filled with epoxy and allowed to dry overnight. 
Step 3. To attach the collection tube, use a 
2Cmm length of 20-ga thin wall stainless steel 
tubing cleaned but not acid etched. Micro-line 
1850 tubing (6 cm) is attached to one end. Using 
suture silk, a 0.4-ml sample tube is tied to the 
stainless steel tubing. The collection tube top is 
removed and pierced from the inside out with a 
30-ga hypodermic needle. The exposed fused sil- 
ica is threaded from the probe into the needle 
and drawn through the collection tube cap with 
the needle. The cap is attached to the outlet 
tubing using Devcon 5-min epoxy. Five minute 
epoxy is also applied to secure the collection tube 
thread and Micro-iine 1850 to the stainless steel 
tubing. When the epoxy has dried, the stainless 
steel tubing (with the attached collection tube) is 
attached to the PE20 inlet tubing. If working 
properly, fluid wiI1 appear at the exposed end of 
the fused silica (and nowhere else) when slowly 
infused through the apparatus. 
A properly flowing unit is ready for use. The 
unit should be filled with the appropriate solu- 
tion. The collection tube is capped, making sure 
to allow space between the end of the fused silica 
and the bottom of the tube so that flow is unob- 
strutted. The upper portion of the collection tube 
should be pierced with a needle to allow air 
release during solution collection. An Alzet 
minipump is attached after activation according 
to the manufacturer’s instructions and the system 
is operating. 
2 nmol [ “HIQUIN (specific activity: 8.0 Ci/mmol). 
Pumps were incubated for 20 h in PBS at room 
temperature, after which time they were attached 
to the units and placed in individual 25ml beakers 
filled with PBS. Beakers with pumps in them 
were covered with parafilm. The dialysis probes 
extended out of the beakers and were submerged 
in different beakers containing 20-ml PBS. All 
beakers were placed in a water bath maintained 
at 37 “C for 22 days. Each day PBS from the 
probe beakers was sampled for tritium content 
and probes were transferred to a new beaker 
containing 20-ml PBS. 
Duplicate 100~~1 aliquots from each beaker 
were counted using Biosafe scintillation cocktail 
(5 ml) in a Beckman IS8100 scintillation counter. 
When the 3 units ceased delivery of [“HIQUIN, 
liquid in the connecting tubing and collection vial 
was collected and remaining radioactivity was 
measured. 
In vivo application 
Animals (25 adult rats) were anesthetized with 
pentobarbital (30 mg/kg) supplemented with 
methoxyfluorane. For each rat, a stainless steel 
cannula (8 mm, 21-ga) was implanted through the 
skull aimed at the right striatum (stereotaxic co- 
ordinates: 0.5 mm anterior, 2.6 mm lateral from 
bregma; 1 mm ventral from skull surface). The 
cannula was secured in place with dental acrylic 
and kept patent with a stylet. The chronic dialysis 
apparatus was inserted 10 days later under anes- 
thesia as described above. Osmotic minipumps 
(lot no, 51943, mean pumping rate 0.55 pi/h, 
mean fill volume 225 ~1) and collection tubes 
were secured subcutaneously through a small in- 
cision in the back of the neck. Each dialysis probe 
was sleeved in a section cut from a 200~~1 pipette 
tip (Fig. 1). A dialysis apparatus containing either 
40 mM QUIN or vehicle (PBS) was inserted 
through the guide cannula. Dental acrylic was 
used to secure the outer pipette sleeve. During 
In vitro application the dialysis period, several animals disconnected 
Chronic dialysis. probes were filled with a solu- either the inlet or outlet tubing. These animals 
tion of 40 mM QUIN in 0.1 M phosphate buffered were anesthetized and the tubing was reattached. 
0.9% saline (PBS; pH 7.4). Alzet minipumps were Infusion probes and pumps were removed after 4 
filled with a solution of 40 mM QUIN containing weeks. 
Histology 
All animals were given an overdose of pento- 
barbitol and perfused through the heart with PBS 
followed by 4% paraformaldehyde in 0.1 M 
sodium phosphate buffer. Brains were post-fixed 
overnight at 40°C and cryoprotected in 20% 
sucrose phosphate buffer. Coronal sections (40 
Izm) were collected on a freezing microtome and 
stained with cresyl violet. 
Materials 
The following items were used for construction 
of the chronic dialysis apparatus: stainless steel 
tubing, 20- and 26-ga thin wall (Small Parts Inc., 
Miami, FL), dialysis fiber (regenerated cellulose 
hollow fiber) MWCO 6000 (stock no. 132275, 
Spectrum Medical Industries, Houston, TX); 
epoxy, 5-min and 2-ton (Devcon, Danvers, MA); 
fused silica capillary tubing, 75 izm inner diame- 
ter x 150 /xm outer diameter (Polymicro Tech- 
nologies, Phoenix, AZ); polyethylene tubing, PE20 
(A-M Systems, Everett, WA); Micro-line (TM) 
1810 and 1850 tubing (Cole-Parmer, Chicago, IL); 
and Alzet minipumps, model 2002 (Alza Corp, 
Palo Alto, CA). 
For testing the apparatus, quinolinic acid 
(Sigma, St. Louis, MO) and [3H]quinolinic acid 
(NEN-Dupont, Bannockburn, IL) were used. For 
in vitro testing, samples containing [3H]QUIN 
were mixed with Biosafe scintillation cocktail 
(Research Products International, Mt. Prospect, 
IL). 
Results 
In uitro dialysis with quinolinic acid 
[3H]QUIN diffused out of all dialysis probes 
for 14-17 days (Fig. 3). After the pumps contain- 
ing [3H]QUIN were attached to the inlet tubing, 
it took 1-2 days for the [3H]QUIN to reach the 
dialysis probe. By day 21 radioactivity levels in all 
3 receptacle beakers were negligible. After that 
time, the percent total [3H]QUIN was deter- 
mined by subtracting the sum of the daily amounts 
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Fig. 3. Mean cumulative percent delivery of 3[H]QUIN over a 
period of 21 days. Mean cumulative delive~ for the 3 pumps 
on day 21 was 95.3%. 
(sum of the daily amounts plus amount remaining 
in the apparatus at the end of the study). The 
percent efficiency of [3H]QUIN dialysis from the 
units was: unit 1, 98.1; unit 2, 94.6; and unit 3, 
93.2. 
In ciuo dialysis' of quinolinic acid 
Damage caused by QUIN dialysi~ consisted of 
atrophy of the right striatum. There was also 
atrophy of surrounding structures in some ani- 
mals, but to a lesser extent (Fig. 4a). Animals that 
received vehicle had only local damage from the 
insertion of the dialysis probe (Fig. 4b). Animals 
from both the QUIN and vehicle groups re- 
mained healthy throughout the duration of the 
dialysis period and for the several weeks they 
were allowed to survive after removal of the 
apparatus. All pumps were inspected visually 
upon removal and found to be empty. 
Discussion 
A system has been described for chronic in- 
tracranial drug administration in the rat using a 
modified in vivo microdialysis probe in combina- 
tion with the Alzet model 2002 osmotic minipump. 
The results presented demonstrate that this sys- 
tem can be used for the chronic administration of 
QUIN with minimal non-specific damage. Each 
pump delivered by osmosis the solute contained 
in approximately 225/zl of solution over a period 
of 19-20 days, when tested in vitro. The dialysis 
units were uniform in function, > 93% of the 
[3H]QUIN initially loaded into the minipump dif- 
fused out of the probe during operation. This 
same apparatus  design was also successfully tested 
in vivo. Histological examination indicated that 
Q U I N  produced damage throughout the stria- 
tum. 
When tested in vitro, [3H]QUIN was not de- 
tected for the first 2 days of sampling. Since the 
inlet tubing was not filled with [3H]QUIN, the 
first 2 days of testing constituted a time course 
for solution (approximately 16/zl) to traverse the 
inlet tubing. Specifications from the pump lot 
used for in vitro tests predicted approximately 17 
days of pumping. This time was lengthened by 
1-2 days for in vitro testing, possibly due to 
continued diffusion of fluid contained in the inlet 
tubing after pump flow had ceased. Since the 
Alza corporation reports that the rate of infusion 
for in vivo oumns is within 5% of in vitro rate. the 
current apparatus design likely delivers drug over 
a similar time period in tissue. 
For in vivo analysis of this apparatus the dose 
of QUIN tested produced extensive destruction 
of the striatum. Brain tissue from control animals 
that received PBS showed no gliosis in excess of 
that expected from probe insertion. Glial fibril- 
lary acidic protein staining of a separate group of 
similarly treated animals also indicated that glio- 
sis in the region of the probe was negligible 
(unpublished results). These results differ from 
Benveniste and Diemer (1987) who reported ex- 
cessive gliosis surrounding chronically implanted 
dialysis fibers. At least two important method- 
ological differences between that report  and the 
present experiment may account for the contrast- 
ing results. Benveniste and Diemer  (1987) re- 
ported excessive glial formation surrounding inac- 
tive acrylic dialysis fibers. In the present study, 
continuous dialysis was performed using regener- 
ated cellulose dialysis fibers. Benveniste and 
Diemer (1987) reoorted astrocvte orocesses ex- 
Fig. 4. a: cresyl violet stained 40/zm section from the right striatum of a rat that received 200 ,u.l of a 40 mM solution of QUIN over 
approximately 3 weeks. Marked atrophy of the striatum is apparent. The enlarged ventricle appears to have resulted from 
shrinkage of surrounding tissue, b: cresyl violet stained 40/.Lm section from the right striatum of a control rat that received 200 ~zl 
of PBS over approximately 3 weeks. Damage appeared non-specific and confined to the area immediately surrounding the probe 
cannula. 
tending into the fiber wall. Continuous dialysis 
may have reduced innervation within and around 
the fiber. In addition, the use of regenerated 
cellulose, rather than acrylic fibers, may also have 
reduced gliosis in the present experiment. In their 
study, Benveniste and Diemer (1987) noted that 
tissue reactions may have been caused by specific 
materials introduced into the brain, rather than 
the method by which they were introduced. 
Use of chronic dialysis for administration of 
drugs may increase the reliability of administra- 
tion, while decreasing non-specific tissue damage. 
Solutions that are pressure injected through an 
intracranially implanted cannula are assumed to 
enter the brain as a spherical drop (Rice et al., 
1985). Variation in drop size directly influences 
the rate and extent of drug diffusion. Efficiency 
of binding, reuptake and degradation of infused 
substances may in turn be influenced by the rate 
of diffusion. Thus, variations in drop size, result- 
ing from pressure injection delivery, may ulti- 
mately produce variability in the diffusion area, 
and in the effect of the infused drug. In addition, 
the use of injection cannulae results in point 
source delivery. These limitations apply to previ- 
ous efforts to induce neural degeneration with 
excitotoxins using Alzet pumps attached to chron- 
ically implanted cannulae. The striatal injury in- 
duced with chronic infusion has resulted in spher- 
ical areas of necrosis limited to the area sur- 
rounding the cannula tip (Mangano and Schwarcz, 
1983; McBean and Roberts, 1983; Rieke et al., 
1989). 
An additional advantage to this system is the 
potential to monitor proper operation throughout 
a period of chronic drug administration. A prop- 
erly functioning unit continuously increases the 
volume of fluid in the collection tube. Although 
in the present in vivo study collection tubes were 
implanted subcutaneously, it is feasible that the 
collection tube could be secured to the skin sur- 
face. Previously, chronic infusion could be moni- 
tored only by inclusion of a radioactive substance 
that was then measured in daily urine samples 
(Mangano and Schwarcz, 1983). 
By using osmosis across a concentration gradi- 
ent with a semipermeable dialysis fiber, no solu- 
tion drop is formed. In fact, there is no net 
change in fluid volume in the brain during the 
course of dialysis. The length of this fiber may be 
varied to increase or decrease the dialysis area. 
Furthermore, any organ that can be penetrated 
by the dialysis probe is a potential site for use of 
this system. In conclusion, we have developed a 
simple and inexpensive technique for administra- 
tion of drugs into brain parenchyma with substan- 
tial advantages over previously used techniques. 
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